RxDoctor Payments DataLook up a doctor →

Preetesh Patel, MD

Interventional Pain Medicine · Roswell, GANPI 1124190079

Payments from drug & device makers

$13,982in general payments, 2019–2025

Across 433 payments — averaging $32.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Abbott$2K
  • Si-bone, Inc.$2K
  • Medtronic$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Nevro Corp.$837
  • plus $3K from 41 others

What the payments were for

  • Travel & lodging$1,0718%
  • Food & beverage$12,78391%
  • Education$1271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,982 in reported general payments places this provider in the 80th percentile of 129 interventional pain medicine providers in Georgia.

See all interventional pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$576,676
Medicare patients
593
Services billed
5,875

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl34$29,980
Xtampza ErOxycodone Myristate39$29,295
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen503$17,086
BelbucaBuprenorphine Hcl16$12,489
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen556$10,739
Buprenorphine31$7,655
MovantikNaloxegol Oxalate14$5,659
Fentanyl29$5,138
Oxycodone Hcl194$2,792
Morphine Sulfate ErMorphine Sulfate97$2,680
Pregabalin133$2,549
Eszopiclone33$1,798
Gabapentin112$1,373
Tramadol Hcl161$1,118
Tizanidine Hcl70$507

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$679$41,78355 claims
Redhill Biopharma Inc.Movantik$76$5,65914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 129 interventional pain medicine providers in Georgia.

Other interventional pain medicine in Roswell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →